VT-104 / Vivace Therap - LARVOL DELTA

Targeting the YAP/TAZ-TEAD pathway with TEAD inhibitors synergizes with chemotherapy and blocks diffuse gastric cancer progression (AACR 2024) - "Therefore, we evaluated the activity and mechanism of TEAD inhibitors in DGC preclinical models. Gastric cancer patient-derived organoids (PDOs) and cell lines were treated with TEAD inhibitors (K-975, VT103, VT104, VT107) and/or 5-fluorouracil (5-FU) for in vitro assays evaluating cell proliferation or invasion. The YAP/TAZ-TEAD pathway is an important driver of gastric cancer growth and metastasis, particularly in DGC where it may promote EMT and cancer stemness. TEAD inhibition reduces gastric cancer growth and invasion in vitro and in vivo in preclinical models and demonstrates synergistic activity with 5-FU chemotherapy. These results suggest a potential role for evaluating the efficacy of TEAD inhibitors in patients with DGC."

Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD44 • CDH1 • KRAS • SNAI2 • TEAD1 • TP53 • YAP1